Hukumar Kula da Magunguna ta Turai (EMA) ta sanar da cewa ta ba da izinin tallace-tallace na sharadi (CMA) don maganin coronavirus na baka na Pfizer, paxlovid.
A cikin ci gaba da yaduwar kwayar cutar omicron damuwa a ciki Turai, EMA ya ce an ba da shawarar kwayar maganin coronavirus ta farko "don kula da COVID-19 a cikin manya waɗanda ba sa buƙatar ƙarin iskar oxygen kuma waɗanda ke cikin haɗarin cutar ta zama mai tsanani."
Hanyar CMA, in ji EMA, ana amfani da ita don hanzarta aiwatar da izini na magunguna "a lokacin larurar lafiyar jama'a."
Tare da amincewar mai kula da Turai, paxlovid ya zama maganin rigakafi na farko da ake bayarwa ta baki wanda aka ba da shawarar a cikin EU don magance COVID-19.
Amincewar paxlovid ya biyo bayan izini a watan Disamba na maganin rigakafin Xevudy, wanda GlaxoSmithKline da Vir Biotechnology suka samar, da kuma Kineret na kamfanin Sweden Sobi, wanda asalin maganin arthritis ne amma yana iya “rage” kumburin da ke da alaƙa da COVID.
Paxlovid's fafatawa a gasa, Merck's Lagevrio (molnupiravir), ya kasance a karkashin la'akari da EMA, kamar yadda tasiri ya tabbatar da kasa da yadda ake tsammani.
Duk Paxlovid da molnupiravir sun sami izini daga Hukumar Kula da Abinci da Magunguna ta Amurka a watan Disambar bara.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- The approval of Paxlovid follows the authorization in December of antibody treatment Xevudy, produced by GlaxoSmithKline and Vir Biotechnology, as well as Kineret by Swedish company Sobi, which was originally an arthritis drug but is able to “reduce” COVID-related inflammation.
- Amid the ongoing spread of the virus’s Omicron strain in Europe, EMA said that the first coronavirus treatment pill has been recommended “for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
- Tare da amincewar mai kula da Turai, Paxlovid ya zama maganin rigakafi na farko da aka ba da ta baki wanda aka ba da shawarar a cikin EU don kula da COVID-19.
